Zacks Investment Research upgraded shares of Agenus (NASDAQ:AGEN) from a hold rating to a buy rating in a research report released on Tuesday. They currently have $2.00 target price on the biotechnology company’s stock.

According to Zacks, “Agenus posted narrower-than-expected loss in the second quarter of 2018 and revenues beat estimates. The company is advancing a combination study of CTLA-4 targeting antibody- AGEN-1884 and its own PD-1 targeting antibody -AGEN-2034 in second line cervical cancer and a filing is expected as early as 2020. The company filed three investigational new drugs (INDs) in 2018 and three additional INDs will be filed by the end of the year. The company also delivered on its partnership commitments with Merck and Incyte with two programs in the clinic this year and a third expected before the end of the year, each triggering a cash milestone. With no approved product in its portfolio and only a few candidates in mid-stages of development including Prophage Series vaccine, the company is still a few years away from bringing a product to market. Meanwhile, shares have underperformed the industry so far this year.”

A number of other brokerages have also commented on AGEN. ValuEngine lowered shares of Agenus from a hold rating to a sell rating in a report on Wednesday, April 18th. BidaskClub lowered shares of Agenus from a strong-buy rating to a buy rating in a report on Monday, June 18th.

Shares of AGEN stock opened at $1.67 on Tuesday. Agenus has a 12 month low of $1.57 and a 12 month high of $6.19. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of -0.11. The firm has a market capitalization of $205.04 million, a price-to-earnings ratio of -1.36 and a beta of 1.62.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. sell-side analysts forecast that Agenus will post -1.57 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. Jane Street Group LLC acquired a new position in Agenus in the 2nd quarter worth $101,000. A.R.T. Advisors LLC acquired a new position in Agenus in the 1st quarter worth $103,000. MetLife Investment Advisors LLC acquired a new position in Agenus in the 4th quarter worth $124,000. Raymond James & Associates acquired a new position in Agenus in the 4th quarter worth $130,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Agenus in the 1st quarter valued at about $197,000. Hedge funds and other institutional investors own 45.51% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Further Reading: Are analyst ratings accurate?

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with's FREE daily email newsletter.